Kuros Biosciences AG

Kuros Biosciences AG

Health CarePharmaceuticals and Biotechnology
  • Price (CHF)1.70
  • Today's Change0.015 / 0.89%
  • Shares traded3.05k
  • 1 Year change-10.55%
  • Beta1.1102
Data delayed at least 15 minutes, as of Dec 01 2022 16:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

  • Revenue in CHF (TTM)15.16m
  • Net income in CHF-11.14m
  • Incorporated1995
  • Employees64.00
  • Location
    Kuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
  • Phone+41 447334747
  • Fax+41 447334740
  • Websitehttp://www.kuros.ch/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Addex Therapeutics Ltd1.25m-21.42m13.49m28.00--0.9212--10.82-0.5532-0.55320.03160.14960.0823--4.6044,546.79-141.40-43.18-187.08-50.38-----1,717.50-279.82---178.630.0532---18.7151.13-18.19--22.97--
Spexis AG0.001.80m20.46m--0.40060.771613.45--
Newron Pharmaceuticals SpA5.83m-14.24m24.07m25.00------4.13-0.7981-0.79810.3265-0.28920.1419--3.50233,049.90-34.70-25.64-38.05-28.1798.1886.47-244.45-216.08---3.331.13--9.594.0029.04---22.60--
Santhera Pharmaceuticals Holding AG163.00k-64.73m38.48m39.00------236.10-1.28-1.280.0032-0.25530.00211.110.0874,179.49-80.91-48.15-168.64-60.86-2,115.3480.16-39,712.27-172.870.372-82.931.52---110.63--17.93---47.47--
Kuros Biosciences AG15.16m-11.14m61.42m64.00--0.7526--4.05-0.3369-0.33690.45622.230.16682.003.33261,293.10-12.26-13.87-13.53-14.6975.45---73.52-269.992.25-2.990.0258--242.0467.0834.54--49.55--
Wockhardt Bio AG313.13m-42.44m82.41m----0.2795--0.2632-0.7606-0.76066.035.680.47921.802.50---6.50-0.7439-8.19-1.2551.4452.97-13.55-1.623.90-3.450.5092--12.15-2.14-107.96---8.03--
Evolva Holding SA11.64m-44.75m85.71m62.00--0.7547--7.37-0.0474-0.04740.01240.10390.07851.132.35171,127.90-30.20-16.27-34.83-17.43-48.26-4.44-384.55-359.290.8091--0.0974--30.990.6225-38.15---18.76--
RELIEF THERAPEUTICS Holding SA7.87m-46.53m133.19m55.00--0.7559--16.93-0.0116-0.01160.0020.03850.03926.094.64143,018.20-23.16-17.42-25.24-18.9281.96---591.50-1,372.002.78-51.300.0247----194.47-343.34--316.02--
Xlife Sciences AG863.90k48.92m166.44m19.005.640.7913.08192.665.595.590.130939.820.0026--2.3245,468.4213.92--16.67--38.79--5,327.34-----0.61380.1615--103.14--148.91------
Molecular Partners AG188.71m117.37m221.49m164.001.750.79531.851.173.523.525.767.730.8249--51.621,157,718.0051.31-29.2458.86-37.44--95.9462.20-322.54----0.0201--4.39-15.79-1.63--3.57--
Data as of Dec 01 2022. Currency figures normalised to Kuros Biosciences AG's reporting currency: Swiss Franc CHF

Institutional shareholders

17.28%Per cent of shares held by top holders
HolderShares% Held
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 20213.28m8.97%
Banque Pictet & Cie SAas of 31 Dec 20211.39m3.81%
Apo Asset Management GmbHas of 31 Oct 20221.16m3.18%
UBS Asset Management Switzerland AGas of 01 Nov 2022196.94k0.54%
Schroder Investment Management (Switzerland) AGas of 30 Nov 2018123.81k0.34%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202070.55k0.19%
Migros Bank AGas of 30 Jun 202137.13k0.10%
BlackRock Asset Management Schweiz AGas of 03 Nov 202223.25k0.06%
Lombard Odier Asset Management (Switzerland) SAas of 31 Aug 202216.90k0.05%
Equinor Asset Management ASAas of 30 Jun 202213.75k0.04%
More ▼
Data from 31 Dec 2021 - 31 Oct 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.